Russian Deputy Prime Minister Tatiana Gólikova announced that Russia will register the Sputnik M vaccine today, which is aimed at people between the ages of 12 and 17.
The official stressed after a meeting with Russian President Vladimir Putin that the vaccine could be available to the population from the end of December 2021.
“The Russian Ministry of Health will register today the Sputnik vaccine for children from 12 to 17 years old. The Sputnik M vaccine for children will be a welcome member of the Sputnik family both in Russia and in global markets, ”its developers said on the official Twitter account.
Sputnik M will be added to Sputnik V, which consists of two doses that uses human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component, and the Sputnik Light which consists of the first dose of the previous one. Sputnik V, developed by the Gamaleya Research Center, was registered for adults in Russia in August 2020 and is more than 91.6% effective.
The Sputnik V vaccine developed by the Gamaleya Institute of Russia has already been authorized in 70 countries but does not yet have authorization from the WHO. During a recent press conference, Dr. Mariângela Simão, WHO Deputy Director General for Access to Medicines, Vaccines and Pharmaceutical Products, iIt stated that the process of listing the emergency use of Sputnik V had been stopped until October 20 “due to a legal procedure.”, since it was necessary for the applicant to sign that he accepted the rules and procedures of the WHO in order to continue with the evaluation.
The Sputnik V vaccine evaluation process was resumed on October 21, so inspections of the plants where the drug is produced could be resumed in the coming weeks. “We will also continue to receive additional data from the Sputnik requester. So this is the process that works for everyone, ”he added.
The waiting time for a vaccine to be included in the WHO list “depends on how quickly the manufacturers send the data,” according to Dr. Simão. “And in some cases, we need to do factory inspections,” he added.
New efficacy studies in San Marino
The Direct Investment Fund (RDIF) that develops the Sputnik vaccine today presented a report from the Ministry of Health of the Republic of San Marino showing that the Russian Sputnik V vaccine is 80% effective against coronavirus infection from the sixth to the eighth month after administering the second dose.
As announced by the Sputnik developers in a statement: “The efficacy of Sputnik V in 6-8 months is much greater than the officially published efficacy of mRNA vaccines. The Sputnik team believes that adenoviral vaccines provide longer-lasting efficacy than mRNA vaccines due to a longer response of antibodies and T cells. “.
“As there is currently an increase in COVID cases in Europe, an effective long-term scientific solution needs to be found. With mRNA vaccines showing decreasing efficacy, it is important to observe the efficacy of the vaccine in 5-6 months, not in 2-3 months as was done previously, and explore the heterologous boost with other vaccines to lengthen the immunity created by mRNA vaccines ”, they expanded from Russia.
The RDIF and Sputnik team has taken the lead by offering a combination vaccine approach to other producers and the single-dose Sputnik Light vaccine as a universal booster. Several combination studies (in Argentina and Azerbaijan) have shown that the immune response of the boost with Sputnik Light is much greater than two injections of the same vaccine.
In December 2021, additional real-world data on the long-term efficacy of Sputnik V.